ShiraTronics Secures $66M to Advance Novel Therapy for Migraine MedTech startup ShiraTronics, Inc. has secured $66 million in Series B funding round to advance implantable neuromodulation device for treatment-resistant migraine to FDA-approved pivotal clinical trials, the company announced last Wednesday. Co-founded in 2018 by Mudit K. Jain, PhD, CEO and partner at Treo Ventures, ShiraTronics leverages advanced technologies to develop an effective therapy for chronic migraines. The company’s series B round was led by a new investor Norwest Venture Partners, with notable contributions from Seroba., the Global BioAccess Fund, and OSF Ventures, alongside other undisclosed strategic investors. Read more: https://nextdigitalhealth.com/funding-news/shiratronics-secures-66m-to-advance-novel-therapy-for-migraine/ #fundingnews #FundingOpportunity #StartupFunding #StartupSuccess #HealthcareNews #MedicalDevice #MigraineTreatment #HealthcareFunding #nextdigitalhealth #Wi4 #vineetagrawal